Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
CorrectionErratum

Correction to “Characterization of human α4β2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells”

Molecular Pharmacology July 2004, 66 (1) 197; DOI: https://doi.org/10.1124/mol.66.1.197
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

See original article:

  • Characterization of Human α4β2-Nicotinic Acetylcholine Receptors Stably and Heterologously Expressed in Native Nicotinic Receptor-Null SH-EP1 Human Epithelial Cells - December 01, 2003

In the above article [Eaton JB, Peng J-H, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo Y-P, Steinlein O, and Lukas RJ (2003) Mol Pharmacol 64:1283-1294], Table 3 was incorrect due to printing errors. The corrected table appears below.⇓

View this table:
  • View inline
  • View popup
TABLE 3

Parameters for interactions of indicated drugs with hα4β2-nAChR in transfected SH-EP1 cells

Results presented in Figs. 6 to 9 and in Tables 1 and 2 are summarized. Functional EC50 values for agonists (column 2), functional IC50 values for antagonists (column 3; functional IC50 values given in parentheses for nicotine and suberyldicholine from fits to the self-inhibitory phase of agonist dose-response profiles for those drugs), and [3H]EBDN binding competition Ki values (column 4), all in micromolar, are expressed to allow comparisons between functional and radioligand binding competition affinities for the indicated ligands (drug; column 1). Also indicated (F/B; column 5) is the ratio between the functional EC50/IC50 and the binding competition Ki value (based on the IC50 value but corrected for the concentration of H-EBDN used in those assays and for the H-EBDN binding KD of 10 pM using the Cheng-Prusoff correction) for each ligand. The notations following the drug name for selected ligands indicate, from results shown in Fig. 9, functional antagonism actions as a noncompetitive inhibitor (N), a competitive inhibitor (C), or a mixed competitive/noncompetitive inhibitor (N/C).

We regret this error and apologize for any confusion or inconvenience it may have caused.

  • The American Society for Pharmacology and Experimental Therapeutics
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 66 (1)
Molecular Pharmacology
Vol. 66, Issue 1
1 Jul 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Correction to “Characterization of human α4β2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells”
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
CorrectionErratum

Correction to “Characterization of human α4β2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells”

Molecular Pharmacology July 1, 2004, 66 (1) 197; DOI: https://doi.org/10.1124/mol.66.1.197

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
CorrectionErratum

Correction to “Characterization of human α4β2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells”

Molecular Pharmacology July 1, 2004, 66 (1) 197; DOI: https://doi.org/10.1124/mol.66.1.197
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Correction to “Sulforaphane Suppresses Polycomb Group Protein Level via a Proteasome-Dependent Mechanism in Skin Cancer Cells”
  • Correction to “The Common LncRNAs of Neuroinflammation-Related Diseases”
  • Correction to “A Novel Semisynthetic Inhibitor of the FRB Domain of Mammalian Target of Rapamycin Blocks Proliferation and Triggers Apoptosis in Chemoresistant Prostate Cancer Cells”
Show more Erratum

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics